Ron Bentsur

Ron Bentsur

Chairman & CEOatNuvectis Pharma· In proxies 2022–2025

Pay in FY2025+124% from the year before · Nuvectis Pharma stock +39.6% the same year

Ron Bentsur was paid $2.6M in FY2025 (Dec), up 124%. Nuvectis Pharma stock rose 39.6% that year.

Pay$100 in the stock at the end of FY22 → $101
Pay is from the Summary Compensation Table of each Nuvectis Pharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Nuvectis PharmaPublic company · 4 yr
    • Chairman & CEO2022 – Present · 4 yrStock in role +465%
  2. Beyond Air, Inc.Public company
    • Director? – PresentNo stock prices for these years
  3. Stemline Therapeutics, Inc.Public company · 17 yr
    • Director2009 – Present · 17 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?